Rafferty Asset Management
AKBA icon

Rafferty Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Rafferty Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$455K Sell
327,110
-171,513
-34% -$236K ﹤0.01% 897
2025
Q4 		$803K Buy
498,623
+16,754
+3% +$35.1K ﹤0.01% 835
2025
Q3 		$1.32M Buy
481,869
+227,915
+90% +$758K ﹤0.01% 736
2025
Q2 		$924K Buy
253,954
+47,324
+23% +$130K ﹤0.01% 776
2025
Q1 		$397K Buy
206,630
+26,878
+15% +$54.9K ﹤0.01% 911
2024
Q4 		$342K Buy
+179,752
New +$312K ﹤0.01% 998
2022
Q2 		– Sell
-702,647
Closed -$504K – 1127
2022
Q1 		$504K Sell
702,647
-35,428
-5% -$75.8K ﹤0.01% 990
2021
Q4 		$1.67M Buy
738,075
+64,136
+10% +$175K 0.01% 720
2021
Q3 		$1.94M Buy
673,939
+78,993
+13% +$226K 0.01% 643
2021
Q2 		$2.25M Sell
594,946
-328,008
-36% -$1.1M 0.01% 653
2021
Q1 		$3.12M Buy
922,954
+628,925
+214% +$2.27M 0.02% 461
2020
Q4 		$823K Sell
294,029
-220,207
-43% -$643K 0.01% 563
2020
Q3 		$1.29M Buy
514,236
+471,362
+1,099% +$4.14M 0.02% 537
2020
Q2 		$582K Buy
+42,874
New +$444K 0.01% 675
2020
Q1 		– Sell
-57,128
Closed -$361K – 602
2019
Q4 		$361K Sell
57,128
-77,688
-58% -$369K 0.01% 750
2019
Q3 		$528K Sell
134,816
-165,115
-55% -$708K 0.01% 656
2019
Q2 		$1.45M Buy
299,931
+174,540
+139% +$993K 0.03% 493
2019
Q1 		$1.03M Buy
+125,391
New +$860K 0.02% 540

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Rafferty Asset Management's AKBA Position: Q1 2026 in Review

Rafferty Asset Management reduced its Akebia Therapeutics (AKBA) stake by 34% in Q1 2026, selling an estimated $236K and leaving 327,110 shares worth $455K. The position accounts for ﹤0.01% of the portfolio, ranked #897.

Rafferty Asset Management first reported a position in AKBA in Q1 2019 and has held it in 18 quarters since. The position peaked at $3.12M in Q1 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Rafferty Asset Management held 327,110 shares of Akebia Therapeutics worth $455K as of Q1 2026.
  • Rafferty Asset Management sold 171,513 Akebia Therapeutics shares in Q1 2026, an estimated $236K.
  • Akebia Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #897 holding.
  • Rafferty Asset Management first reported a position in Akebia Therapeutics in Q1 2019 and has held it in 18 quarters since.
  • Rafferty Asset Management's Akebia Therapeutics position peaked at $3.12M in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.